Join our mailing list and receive the monthly BioVox newsletter for free!

RELATED ARTICLES
Fresh insights into the future of cell therapy

The first edition of Science for health was held in the heart of Brussels on September 11 with a focus on cell therapy. The event attracted over 3…


Living on the edge: the challenge of doing things differently in cell therapy

Belgian company Celyad is a trailblazer in oncology: its T cell therapies based on NK receptors are cutting edge even for CAR-T. At the Science fo…


Curing hay fever - ASIT Biotech allergy vaccines

The sun is shining, the grass is green, but hay fever season is at its peak! Many people (myself included) will spend a lot of money on antihistam…

POPULAR TAGS

Celyad Announces Registration of the first patient in the Belgian THINK trial

Written by LVS on in the category news with the tags , , .


Cell-based immunotherapy specialist Celyad today announced that the first patient of the Therapeutic Immunotherapy with NKR-2 (THINK) trial started cell processing in Belgium. Blood was collected from this patient and first CAR-T NKR-2 dose level infusion (3x108 cells) is expected in January 2017.

“We are pleased to announce that the first patient has been registered in our Belgian Phase Ib trial of CAR-T NKR-2. After witnessing evidence of activity in our initial safety studies, we are enthusiastic about reporting data from this trial in 2017,” said Christian Homsy, CEO of Celyad. “We look forward to expanding the trial to U.S.-based institutions and I would like to thank our clinical partners, and the Celyad team for enabling this milestone.”

Dr. Frédéric Lehmann, VP Clinical Development & Medical Affairs commented: “This is an important moment for Celyad. The THINK trial is aimed to demonstrate that CAR-T NKR-2 cells can deeply transform the way we treat cancer patients. The team keeps on showing its awe-inspiring ability to deliver in Research and Development, and the Company has now reached a cardinal inflection point to emerge as a key player in the CAR-T space.”

Read more on Celyad here.
You might also like: CAR-T: the T-cell training program to fight cancer

RELATED ARTICLES
Fresh insights into the future of cell therapy

The first edition of Science for health was held in the heart of Brussels on September 11 with a focus on cell therapy. The event attracted over 3…


Living on the edge: the challenge of doing things differently in cell therapy

Belgian company Celyad is a trailblazer in oncology: its T cell therapies based on NK receptors are cutting edge even for CAR-T. At the Science fo…


Curing hay fever - ASIT Biotech allergy vaccines

The sun is shining, the grass is green, but hay fever season is at its peak! Many people (myself included) will spend a lot of money on antihistam…

POPULAR TAGS

Sign up to our Mailing List to receive updates
of our latest News, Events & Magazines

Itera Life Science Janssen UGent XpandInnovation GSK Turnstone V-Bio Ventures KU Leuven Flanders.bio Biowin

ABOUT BIOVOX - Sharing Life Sciences Innovations

BioVox showcases interesting life sciences breakthroughs for and from Belgian innovators. Through our partnership with BioCentury we share relevant worldwide innovations and business updates while our local journalists focus on regional highlights. 

Interested to get involved? Get in touch! We are looking for content, writers and partners! Blogs are available for research institutes, companies and freelance experts.

You want to reach out to the biotechnology and life sciences community, targetting selected audiences? Discover our sponsor and publication opportunities as well as tailored packages!

Contact BioVox via news@biovox.be or by completing the contact form.